Conclusion
Bumetanide tablets combined with valsartan are remarkably effective for elderly patients with CGN. This combined method can substantially improve the renal function and hemodynamics of the patients, so it has a high clinical application value in the future.
Methods
Data from 122 elderly patients with CGN admitted to Pingdingshan First People's Hospital from April 2019 to January 2020 were analyzed retrospectively. Among them, 65 patients treated with bumetanide tablets combined with valsartan were assigned to a study group and the other 57 patients treated with bumetanide tablets alone were assigned to a control group. The clinical efficacy, renal function, hemodynamics and inflammatory factors of the two groups were compared, and the incidence of adverse reactions during treatment was calculated. The risk factors of unfavorable prognosis were analyzed by multiple logistics regression.
Objective
This study was designed to determine the efficacy of bumetanide tablets combined with valsartan for the treatment of elderly patients with chronic glomerulonephritis (CGN) and its effects on renal function and hemodynamics.
Results
The study group showed a significantly higher total response rate than the control group (P<0.05), and no notable difference was found in the incidence of adverse reactions between the two groups (P>0.05). Before treatment, the examination results of renal function and hemodynamics of the two groups were not significantly different (P>0.05), and the results of both groups were improved after treatment (P<0.05). Furthermore, the study group showed significantly higher levels of renal function and hemodynamics and lower levels of inflammatory factors than the control group after treatment (P<0.05). Older age (OR: 1.883, 95% CI: 1.226-2.892), higher post-treatment blood urea nitrogen (OR: 4.328, 95% CI: 1.117-16.778) and lower post-treatment end-diastolic flow velocity (OR: 0.419, 95% CI: 0.117-0.992) were independent risk factors for unfavorable prognosis of patients.